secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001193125-22-311777
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Biopharma enters into $125M at-the-market equity sales agreement with Stifel
--------------------------------------------------------------------------------

- Agreement with Stifel for up to $125M of common stock sales in at-the-market offerings.
- Stifel will receive a commission of 3.0% of gross sales proceeds from shares sold.
- Replaces prior ATM agreement with Jefferies LLC, which was terminated on Dec 22, 2022.
- Company has no obligation to sell shares; sales are at its sole discretion.
- Prospectus supplement filed under existing Form S-3 registration statement (333-263541).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/0001193125-22-311777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312522311777/d402595d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer